VivoSeq
Infectious Disease

Chronic Hepatitis C Virus Infection

67

Pipeline Programs↗

1

Active Trials↗

23

Companies Involved↗

Chronic Hepatitis C Virus Infection is a moderately active landscape with 67 programs across 23 companies. The most active players are Peregrine Pharmaceuticals, XTL Biopharmaceuticals, Santaris Pharma A/S. 20 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Peregrine Pharmaceuticals

1 program

Phase 1X

XTL Biopharmaceuticals

1 program

Phase 1S

Santaris Pharma A/S

1 program

Phase 2Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

61 of 69 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody46%Vaccine23%Protein / enzyme11%RNA therapy11%

Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 100% of 71 pipeline programs.

Analysis

Trial Status

40

clinical trials

Completed31 · 78%
Unknown status4 · 10%
Terminated3 · 8%
Withdrawn1 · 3%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

40 trials

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02772003·33 enrolled
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Completed·Roche logoRoche·Phase 2·NCT01220947·421 enrolled
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
Completed·UUniversity of Colorado, Denver·Phase 4·NCT01097395·35 enrolled
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
Completed·AbbVie logoAbbVie·Phase 3·NCT02442284·99 enrolled
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
Completed·PPeregrine Pharmaceuticals·Phase 1·NCT00128271·32 enrolled
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 2·NCT00035945
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
Completed·Gilead logoGilead·N/A·NCT02783976·25 enrolled
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
Completed·Astellas logoAstellas·Phase 2·NCT00047814·48 enrolled
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
Completed·Gilead logoGilead·Phase 2·NCT02781571·79 enrolled
Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection
Completed·VVirginia Commonwealth University·Phase 3·NCT00248339·150 enrolled
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT02114177·310 enrolled
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection
Completed·Gilead logoGilead·Phase 3·NCT02722837·119 enrolled
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
Completed·AbbVie logoAbbVie·Phase 3·NCT02707952·295 enrolled
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01241760·744 enrolled
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT01492426·605 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)